Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Persistence of Patients Receiving Topical Glaucoma Monotherapy in an Asian Population

Persistence of Patients Receiving Topical Glaucoma Monotherapy in an Asian Population SOCIOECONOMICS AND HEALTH SERVICES SECTION EDITOR: PAUL P. LEE, MD ONLINE FIRST Persistence of Patients Receiving Topical Glaucoma Monotherapy in an Asian Population Desmond T. L. Quek, MRCSEd; Geok-Teng Ong, BSc; Shamira A. Perera, FRCOphth; Ecosse L. Lamoureux, PhD; Tin Aung, FRCOphth, PhD Objective: To determine the persistence rates of patients decreased to 11.5% (320 of 2781) after 3 years. Prosta- who started taking topical intraocular pressure (IOP)– glandin analogues had better persistence rates at 1 year lowering monotherapy in a Singapore eye hospital. compared with timolol maleate (29.6% vs 23.7%; P=.004) and all other medications combined (29.6% vs 20.6%; Methods: This was a retrospective review of patients who P.001). Those who were not persistent at year 1 were started taking a single IOP-lowering medication be- younger (P .001) and more likely to not be Sin- tween October 1, 2005, and September 30, 2006. Phar- gaporean (P=.008), not receiving government subsidies macy dispensing records were traced for 3 years from the (P.001), and receiving unilateral therapy (P.001). date of first prescription. A patient was defined as per- sistent if he or she was prescribed the same medication Conclusions: In this hospital-based study, the persis- before or within 90 days http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Persistence of Patients Receiving Topical Glaucoma Monotherapy in an Asian Population

Download PDF
6 pages

Loading next page...
 
/lp/american-medical-association/persistence-of-patients-receiving-topical-glaucoma-monotherapy-in-an-nBHZuJuELG

References (30)

Publisher
American Medical Association
Copyright
Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/archophthalmol.2010.345
pmid
21220621
Publisher site
See Article on Publisher Site

Abstract

SOCIOECONOMICS AND HEALTH SERVICES SECTION EDITOR: PAUL P. LEE, MD ONLINE FIRST Persistence of Patients Receiving Topical Glaucoma Monotherapy in an Asian Population Desmond T. L. Quek, MRCSEd; Geok-Teng Ong, BSc; Shamira A. Perera, FRCOphth; Ecosse L. Lamoureux, PhD; Tin Aung, FRCOphth, PhD Objective: To determine the persistence rates of patients decreased to 11.5% (320 of 2781) after 3 years. Prosta- who started taking topical intraocular pressure (IOP)– glandin analogues had better persistence rates at 1 year lowering monotherapy in a Singapore eye hospital. compared with timolol maleate (29.6% vs 23.7%; P=.004) and all other medications combined (29.6% vs 20.6%; Methods: This was a retrospective review of patients who P.001). Those who were not persistent at year 1 were started taking a single IOP-lowering medication be- younger (P .001) and more likely to not be Sin- tween October 1, 2005, and September 30, 2006. Phar- gaporean (P=.008), not receiving government subsidies macy dispensing records were traced for 3 years from the (P.001), and receiving unilateral therapy (P.001). date of first prescription. A patient was defined as per- sistent if he or she was prescribed the same medication Conclusions: In this hospital-based study, the persis- before or within 90 days

Journal

JAMA Ophthalmology – American Medical Association

Published: May 1, 2011

There are no references for this article.